Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart? - 2Famous Rough terrain Vehicles for 2024
- 3Interstellar comet 3I/ATLAS isn't an alien spacecraft, astronomers confirm. 'In the end, there were no surprises.'
- 4Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts'
- 5How Much Has the Iran War Cost the Average American Per Day?
- Prehistoric wolf’s gut frozen in time reveals an ice age giant
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- 10 Moving Design Frill for Summer 2023
- From Representative to Business visionary: Private issue Victories
- The 20 Most sultry Style of the Time
- Examination In progress into Abuse of Japanese Government-Supported Advance
- Ukraine apologizes to Finland for crashed drones
- Why are malnutrition deaths soaring in America?
- Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
